Update 5th May 2026.
Biotechnology company MimiVax Inc. and Roswell Park Comprehensive Cancer Center today jointly announced the launch of a phase 2 clinical trial (NCT06202066) evaluating SurVaxM in combination with temozolomide in patients with progressing neuroendocrine tumours, also known as NETs. The study is being conducted at Roswell Park in Buffalo, New York, under the direction of principal investigator Dr. Jasmeet Kaur.
This trial has changed course. It started in 2021 as a phase 1 trial for NETs. A separate trial then added Temozolomide as a combo treatment. Then Phase 2 of the clinical trial gathered all the data and the original trial continues with the Temozolomide combo with SurVaxM but restricted to grade 3 patients i.e. well differentiated G3 NET and poorly differentiated Neuroendocrine Carcinoma (NEC).
What are cancer vaccines?
I remember seeing a comment by a NET Specialist on twitter saying, “We need vaccines”. This was in response to a tweet from another NET Specialist reporting dismal data from an immunotherapy drug for Neuroendocrine Carcinomas. In 2020/2021, the word vaccine has been used a lot, but this specialist was not inferring anti-viral treatment, he was talking about “cancer vaccines”, an emerging discipline in science where vaccines act as an immunostimulant to treat cancer. This prompted me to look around and found this trial which may be of interest to you. However, before anyone gets too excited, this is very early days in the study of SurVaxM in Neuroendocrine Cancer. The vaccine is also being trialled in in Malignant Glioma/gliomablastoma (brain tumours) and Multiple Myeloma (blood cancer).
What is SurVaxM?
SurVaxM is a first-of-its-kind, patented peptide mimic immunotherapeutic vaccine (immunotherapy) that targets survivin, a cell-survival protein present in 95 percent of glioblastomas and many other cancers. It is engineered to recognize survivin-expressing cancer cells as foreign and stimulate patients’ own immune response to control tumour growth and recurrence. While vaccines are typically thought of as ways to prevent diseases, vaccines can also be used in a therapeutic mode as an immunostimulant (e.g., to treat cancer). SurVaxM is delivered through simple subcutaneous injection. MimiVax is leading on this. It’s a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. Their proprietary product portfolio is based on technology licensed from Roswell Park Comprehensive Cancer Center that targets survivin, a cell-survival protein that is present in most cancers and rarely detectable in normal tissue. Their therapies are designed to stimulate immune responses to control tumour growth and recurrence. MimiVax has an exclusive license to globally commercialize SurVaxM, as well as an extensive worldwide patent portfolio for SurVaxM and other products in development.
What is this phase 2 trial?
This phase 2 trial studies these primary objectives:
- To determine the clinical efficacy (progression free survival [PFS]) of combining temozolomide and SVN53-67/M57-KLH peptide vaccine (SurVaxM) in patients with progressing NECs.***
- To evaluate the safety and toxicity of the study drug combination (temozolomide + SurVaxM) in patients with progressing NECs.***
*** I believe this must be a typo as the acceptance criteria clearly states “Measurable, pathologically confirmed diagnosis of neuroendocrine tumor of gastrointestinal, pancreatic, or thoracic origin with ki67>20% (well-differentiated G3 NETs) or neuroendocrine carcinoma of any origin excluding small cell lung carcinoma”
Always check the acceptance criteria (inclusion and exclusion criteria) on any clinical trial. You can find these at reference 3 below.
Any data from this trial?
Keep an eye on the resources below, particularly 5 and 6 below.
Read more here
Resource links here:
- Minivax Website: Click here
2. Clinical Trials Document Phase 1 NCT06202066: Click here
3. Clinical Trials Document Phase 2 – (as above – it has been amended)
4. Clinical Trials Document adding Temozolomide NCT03879694 (trial now closed)
5. NET Research Foundation coverage: Click here
6. Roswell Park Trial page: Click here
Worth noting this trial is in collaboration with Roswell Park Comprehensive Cancer Center (led by Dr Renuka Iyer), the US National Cancer Institute (NCI) and NET Research Foundation.
Also check out an excellent summary of the trial including a patient story and a video clip from Dr Iyer over on NET Research Foundation – click here
Click here to enter Ronny’s Clinical Trials Archive
General Clinical Trials Disclaimer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net
The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
Disclaimer
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Finally
Whenever I post about a trial or study, some people get excited without understanding that these new treatments and capabilities can very often take years to come to fruition and it’s also possible that clinical trials can be halted, or that national approval agencies will not approve the final product. Plus, not everyone will be eligible, so always check the exclusion and inclusion criteria in the relevant clinical trials document. Please bear that in mind when reading studies/clinical trials posted on RonnyAllan.NET
Click here and answer all questions to join my private Facebook group
- Ronny Allan’s Newsletter covering August 2026
Summary of August 2026 on RonnyAllan.NET August was similar to the other months of this year but like July, views are down on the previous two months due to 50% of the month spent on holiday. Still a reasonable blog performance – I can’t complain. Other key targets met were three more editions of the Spotlight… Read more: Ronny Allan’s Newsletter covering August 2026 - External Beam Radiation Therapy (EBRT) for Neuroendocrine Neoplasms
Disclaimer: The information in this section is for education only and does not represent a standard care pathway or service. These treatments are not suitable for everyone, and careful patient selection by an experienced multidisciplinary team is essential. Always discuss your individual situation with your own specialist team. External Beam Radiation Therapy (EBRT) is… Read more: External Beam Radiation Therapy (EBRT) for Neuroendocrine Neoplasms - 2026 Surveillance Update from Ronny Allan: “See you in 12 months”
It’s only a couple of weeks since I celebrated my 16th year since diagnosis of metastatic small intestine Neuroendocrine Tumour (NET) at Grade 2 on 26th July 2010. Thinking back to that period of my life, I’m happy but also slightly amazed to be celebrating such a long milestone having been diagnosed with cancer at… Read more: 2026 Surveillance Update from Ronny Allan: “See you in 12 months” - Spotlight: Selenium in Neuroendocrine Tumours (NETs)
Before you read this This information is designed to help you understand how vitamins and minerals work in the body and how certain NET‑related factors might influence them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs vary widely. If you… Read more: Spotlight: Selenium in Neuroendocrine Tumours (NETs) - Spotlight: Potassium in Neuroendocrine Tumours (NETs)
Before you read this This information is designed to help you understand how vitamins and minerals work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely.… Read more: Spotlight: Potassium in Neuroendocrine Tumours (NETs) - Spotlight: Magnesium in Neuroendocrine Tumours (NETs)
Before you read thisThis information is designed to help you understand how vitamins and minerals work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely. If you… Read more: Spotlight: Magnesium in Neuroendocrine Tumours (NETs) - Ronny Allan’s Newsletter covering July 2026
Summary of July 2026 on RonnyAllan.NET July was similar to the other months of this year but views down on the previous two months due to 50% of the month spent on holiday. Still a reasonable blog performance. Other key targets met were three more editions of the Spotlight series on vitamins and minerals. See… Read more: Ronny Allan’s Newsletter covering July 2026 - 16 years since diagnosis, I’m still here
I finally made 16 years since I was diagnosed on 26th July 2010. A milestone I was not certain at the time I would reach. However, as things progressed, as treatment was administered, and as I got used to living with Neuroendocrine Cancer, I eventually became more confident this was a possibility with the help […]
- Spotlight on Cushing’s Syndrome in Neuroendocrine Neoplasms
Intro Cushing’s syndrome is one of the most challenging hormonal complications seen in people with neuroendocrine neoplasms (NENs). It can be subtle, severe, or even life‑threatening — and it is often misunderstood. Many patients struggle for months or years before receiving a correct diagnosis, partly because the symptoms overlap with everyday conditions such as weight… Read more: Spotlight on Cushing’s Syndrome in Neuroendocrine Neoplasms - 14th July 2026 – Ronny Allan hits 3 million blog views!
Today, 14th July 2026, I can confirm the 3 million views milestone has been reached. MASSIVE THANKS to you guys for reading and sharing. When I first set up this blog in April 2014, it was just to help spread awareness (….and collect a few pennies) whilst I was walking the 84 miles of… Read more: 14th July 2026 – Ronny Allan hits 3 million blog views! - Spotlight: Zinc in Neuroendocrine Tumours (NETs)
Before you read thisThis information is designed to help you understand how vitamins work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely. If you have… Read more: Spotlight: Zinc in Neuroendocrine Tumours (NETs) - Neuroendocrine Tumours – Iron
Disclaimer: This Spotlight provides general educational information about Iron. It is not a substitute for medical advice. Individual needs vary, particularly for those with conditions affecting digestion, absorption, or chronic blood loss. Always consult your medical team before making changes to supplements or nutrition. Before I knew I had metastatic Neuroendocrine Tumours, I was diagnosed… Read more: Neuroendocrine Tumours – Iron - Ronny Allan’s Newsletter covering June 2026
Headline – half yearly point bonus edition Summary of June 2026 on RonnyAllan.NET June was similar to the other months of this year but slightly down on the previous two months due to holiday. Still a strong blog performance. Other key targets met were three more editions of the Spotlight series on primary NET types (colon, thymic… Read more: Ronny Allan’s Newsletter covering June 2026 - Clinical Trials PRRT: From 177Lu to 225Ac: The DOTA-LM3 Antagonist Journey
Disclaimer:Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over… Read more: Clinical Trials PRRT: From 177Lu to 225Ac: The DOTA-LM3 Antagonist Journey - Clinical Study from the Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET
Disclaimer:Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the… Read more: Clinical Study from the Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Discover more from Ronny Allan - Living with Neuroendocrine Cancer
Subscribe to get the latest posts sent to your email.
It’s too late for my husband, the disease that had many options for treatment took him out on January 3, 2021. We were taken by surprise when we finally got back to UChicago Medicine, after treatment for his disease had to be put on hold due to Covid 19. He was diagnosed with Multiple Myleoma. Turns out the MM was aggressive and took presedence over the liver mets. After 10 weeks of treatment for MM he had a 50% improvement for that cancer. Unfortunately, there was nothing to offer the NET due to tumor growth and further damage to the liver from the MM chemo.
I will continue to follow progress for new treatments for NETS.
Thank you, Ronny for continuing to post.
Many blessings,
Juliette
So sorry to hear Juliette. Sincere condolences 🙏